BillionToOne Posts 84% Q1 Revenue Surge to $108.4M and Lifts 2026 Guidance
BillionToOne delivered Q1 revenue of $108.4 M, up 84% year-over-year, and increased gross margin to 73% from 64%, driving $17.8 M operating income versus a $2.3 M loss. It raised full-year 2026 revenue guidance to $450–465 M, targeting 48%–52% growth while maintaining profitability.
1. Q1 Financial Performance
BillionToOne reported total Q1 revenue of $108.4 M, an 84% increase from $59.0 M a year earlier, driven by prenatal clinical testing revenue of $96.5 M (+72%) and oncology testing revenue of $10.7 M (+392%). The company delivered 188,000 tests (+44%) and lifted overall ASP to $571 (+28%).
2. Margin and Profitability Gains
Gross profit rose to $79.1 M, yielding a 73% margin versus 64% in Q1 2025, while operating income reached $17.8 M compared to a $2.3 M loss. Net income was $18.0 M, or $0.34 per diluted share, reversing the prior year’s $4.0 M loss.
3. Guidance Raise and Outlook
Management raised full-year 2026 revenue guidance to a range of $450 M–$465 M (48%–52% growth over 2025) from $430 M–$445 M, and expects to sustain profitability near current levels despite continued investments. Cash flow from operations minus capital expenditures totaled $11.0 M in Q1.
4. Product Launch and Market Expansion
In May, the company launched Unity Confirm, a non-invasive circulating fetal cell confirmation assay using its Fetal Cell Capture™ technology. BillionToOne also expanded payor contracts to cover 300 M contracted lives in the U.S., enhancing market access for its prenatal and oncology offerings.